TREATMENT OF KNEE OSTEOARTHRITIS WITH SM04690 IMPROVED WOMAC A1 'PAIN ON WALKING' RESULTS FROM A 52 WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR, WNT PATHWAY INHIBITOR

被引：5
|
作者：
Kennedy, S. [1 ]
Ghandehari, H. [1 ]
Swearingen, C. [1 ]
Tambiah, J. [1 ]
Hochberg, M. [2 ]
机构：
[1] Samumed LLC, San Diego, CA USA
[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.5547
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0061
引用
收藏
页码：81 / 82
页数：2
相关论文
共 50 条
  • [31] INTEGRATED SAFETY SUMMARY OF THE NOVEL, INTRA-ARTICULAR AGENT LORECIVIVINT (LOR; SM04690), A CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, IN SUBJECTS WITH KNEE OSTEOARTHRITIS
    Simsek, I.
    Swearingen, C.
    Kennedy, S.
    Tambiah, J.
    Damatarca, C.
    Yazici, Y.
    Lane, N.
    Hochberg, M.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S606 - S607
  • [32] COMPARISON OF INTRA-ARTICULAR SHAM AND VEHICLE INJECTION FROM A PHASE 2B TRIAL OF SM04690, A SMALL-MOLECULE WNT INHIBITOR, FOR KNEE OSTEOARTHRITIS
    Yazici, Y.
    Tambiah, J.
    Swearingen, C.
    Kennedy, S.
    Strand, V.
    Cole, B.
    Hochberg, M.
    Bannuru, R.
    McAlindon, T.
    OSTEOARTHRITIS AND CARTILAGE, 2019, 27 : S241 - S242
  • [33] The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
    Yazici, Yusuf
    Kennedy, Sarah
    Swearingen, Chris
    Tambiah, Jeyanesh
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [34] RESULTS FROM A SINGLE CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF INTRA-ARTICULAR ONABOTULINUMTOXINA FOR OSTEOARTHRITIS KNEE PAIN
    Kalunian, K. C.
    Arendt-Nielsen, L.
    Turkel, C. C.
    DeGryse, R.
    McAlindon, T. E.
    Boon, A. J.
    Jiang, G. -L.
    OSTEOARTHRITIS AND CARTILAGE, 2014, 22 : S192 - S192
  • [35] THE NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR LORECIVIVINT (LOR; SM04690), WHICH MODULATES THE WNT PATHWAY, IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS FROM A PHASE 2B TRIAL
    Yazici, Y.
    Kennedy, S.
    Swearingen, C.
    Tambiah, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 809 - 810
  • [36] Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study
    Krupka, E.
    Jiang, G. -L.
    Jan, C.
    OSTEOARTHRITIS AND CARTILAGE, 2019, 27 (11) : 1599 - 1607
  • [37] THE NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR LORECIVIVINT (LOR; SM04690), WHICH MODULATES THE WNT PATHWAY, IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS FROM A PHASE 2B TRIAL
    Yazici, Yusuf
    Kennedy, Sarah
    Swearingen, Christopher I.
    Tambiah, Jeyanesh
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 120 - 121
  • [38] Intra-articular hyaluronan is without clinical effect in knee osteoarthritis: a multicentre, randomised, placebo-controlled, double-blind study of 337 patients followed for 1 year
    Jorgensen, Anette
    Stengaard-Pedersen, Kristian
    Simonsen, Ole
    Pfeiffer-Jensen, Mogens
    Eriksen, Christian
    Bliddal, Henning
    Pedersen, Niels Wisbech
    Bodtker, Soren
    Horslev-Petersen, Kim
    Snerum, Lennart Ortoft
    Egund, Niels
    Frimer-Larsen, Helle
    ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (06) : 1097 - 1102
  • [39] A SINGLE CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF INTRA-ARTICULAR ONABOTULINUMTOXINA AS TREATMENT FOR OSTEOARTHRITIS KNEE PAIN: RESULTS FROM THE EXPERIMENTAL PAIN MODELS
    Arendt-Nielsen, L.
    Jiang, G. -L
    DeGryse, R.
    Turkel, C. C.
    OSTEOARTHRITIS AND CARTILAGE, 2014, 22 : S26 - S26
  • [40] RADIOGRAPHIC OUTCOMES WERE ASSOCIATED WITH PAIN AND FUNCTION RESPONSES: POST-HOC ANALYSIS FROM A PHASE 2 STUDY OF A WNT PATHWAY INHIBITOR, SM04690, FOR KNEE OSTEOARTHRITIS TREATMENT
    Swearingen, C.
    Tambiah, J.
    Gibofsky, A.
    Lane, N.
    McAlindon, T.
    Hochberg, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 793 - 793
12345